Abstract 357MO
Background
Nasopharyngeal carcinoma (NPC) is not commonly observed in adolescents. The late sequelae and long-term survival outcomes diverge between adult and adolescent survivors of NPC. This study was to compare the differences between these two cohorts and evaluate the socio-demographic and clinical factors that have the most significant impact on different aspects of quality of life.
Methods
A total of 420 survivors could be included (195 adolescent and 225 adult survivors). To balance the influence of covariates and potential bias, we used the propensity score matching (PSM) method to match adolescent and adult patients at a ratio of 1:1. Ultimately, we included 155 adolescent and 155 adult survivors in the subsequent analysis. The EORTC QLQ-C30 consists of 30 items spread across 15 dimensions, comprising of 5 functional dimensions, 1 dimension measuring Global health status/QoL, and individual symptom items. The functioning and QoL scales are such that a higher score indicates better health, whereas a higher score on the symptom scales indicates a higher severity of symptoms.
Results
In terms of Global health status, adolescent patients had higher scores than those of adult patients (adolescent: 80.2±12.7; adult: 77.2±11.5; P=0.027). Furthermore, there were also differences in the Functional Scale/Items. Adolescent patients scored higher in Physical functioning (adolescent: 98.5±4.6; adult: 95.1±7.0; P<0.001), Role functioning (adolescent: 97.0±9.2; adult: 90.5±15.2; P<0.001),and Social functioning (adolescent: 96.0±9.0; adult: 93.5±11.8; P=0.038) but had worse Cognitive functioning (adolescent: 88.3±9.9; adult: 93.8±12.6; P<0.001) scores than adult patients. There were also differences in the symptom scale/items, including insomnia (adolescent: 1.9±7.8; adult: 13.1±22.3; P<0.001), constipation (adolescent: 1.29±7.5; adult: 8.0±17.4; P<0.001) and diarrhea (adolescent: 0.65±4.6; adult: 2.8±9.2; P=0.010).
Conclusions
We can infer that adolescent NPC patients are a particular group of patients that, compared to adult patients achieve better survival outcomes, and experience less treatment-related long-term toxicity, and a higher quality of life in the long term.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358MO - Quality-adjusted life-year and life-year estimates for patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the combined positive score 1-19 subgroup treated with pembrolizumab +/- chemotherapy vs cetuximab-containing regimens
Presenter: Philipp Ivanyi
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 357MO and 358MO
Presenter: Pei Jye Voon
Session: Mini oral session: Head and neck cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session: Head and neck cancer
Resources:
Webcast
359MO - Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
Presenter: Shan-Shan Guo
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
360MO - Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
Presenter: Xinrui Chen
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
361MO - Characterizing the role of NSD family of histone methyltransferases in the head and neck squamous cell carcinoma tumor immune microenvironment
Presenter: Yanis Boumber
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 359MO, 360MO and 361MO
Presenter: Bhumsuk Keam
Session: Mini oral session: Head and neck cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session: Head and neck cancer
Resources:
Webcast